Intellectual Property


By protecting our core technology platform and by creating new protections for API formulations based on BEPO, we maintain a competitive advantage that gives us resources to reach our goal: provide best-in-class medicine for all.


National Patents already issued:




02 Aug 2014, Volume 232, Issue 3, pp 561-574

Retroinverso analogs of spadin display increased antidepressant effects
Julie Veyssiere, Hamid Moha ou Maati, Jean Mazella, Georges Gaudriault, Sébastien Moreno, Catherine Heurteaux, Marc Borsotto

View online article


January 2012, Volume 62, Issue 1, Pages 278–288

Spadin as a new antidepressant: Absence of TREK-1-related side effects
H. Moha ou Maati, J. Veyssiere, F. Labbal, T. Coppola, C. Gandin, C. Widmann, J. Mazella, C. Heurteaux, M. Borsotto

View online abstract